STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #590 by analyst upside · 2026-08-13
LEGN
Legend Biotech Corporation
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+152.3%
implied upside to consensus target
Current Price $20.65
Consensus Target $52.1
Bull Target $80.0
Bear Target $27.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
6
Hold
4
Sell
0
52-Week Low $16.24
52-Week High $38.35
YTD Return -4.0%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E 21.3x
EPS (TTM) $-0.47
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.3B
Profit Margin -7.2%
52-WEEK RANGE
52-Week Low $16.24
52-Week High $38.35
Current Price $20.65
Bear Target $27.0
Bull Target $80.0
● Now $20.65 ● Target $52.1
TRADING DATA
Avg Volume 2.7M
YTD Return -4.0%
Analyst Count 15
Consensus Buy
Upside to Target +152.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Legend Biotech Corporation (LEGN) is currently trading at $20.65 with a Wall Street consensus price target of $52.1, implying potential upside of 152.3% over the next 12 months. 15 analysts currently cover LEGN, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $80.0, while the most cautious has a target of $27.0.

LEGN operates in the Healthcare sector with a market capitalisation of $4B. The stock is down 4.0% year-to-date and is currently trading near the lower end of its 52-week range of $16.24 – $38.35.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LEGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-06-03 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-03 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-18 31% win rate (48 calls)
TD Cowen - Reiterated
Hold → Hold 2026-05-13 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-13 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-13 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-04-21 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-04-15 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
35
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →